(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...
Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...
In an expansion of its previous moves to cut insulin prices, Sanofi will cap the price of each of its insulin products at $35 per month in the U.S. regardless of a patient's insurance status. The move ...
A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...
The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo Nordisk A/S’ Novolog (insulin aspart), a ...
Here are nine new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Dextroamphetamine extended-release ...
Biocon Biologics, India’s pride in global biotech, has just scored a major win. The US Food and Drug Administration (USFDA) has approved Kirsty, a fast-acting insulin used to treat diabetes. Kirsty is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback